Please select the option that best describes you:
Are you using maintenance lurbinectedin with immunotherapy in the first-line treatment of extensive stage small cell lung cancer?
Answer from: Medical Oncologist at Community Practice
Yes. I am encouraged by the recent IMforte data demonstrating both PFS and OS benefit with the addition of maintenance lurbinectedin (Paz-Ares, Lancet 2025). Landmark PFS at 6 months approximately doubled (42% vs 19%) and OS at 1 year was 56% vs 44% with atezo+lurbi vs atezo alone. The rate of attri...
Sign In or Register to read more
Answer from: Medical Oncologist at Community Practice
I think it is an option for many patients, but I'll admit that with the FDA approval of tarlatamab (Mountzios et al., PMID 40454646), I find myself not reaching for this option for a multitude of reasons. While it is true that the IMForte study met its primary endpoint, demonstrating both a PFS and ...